FRACTURE RISK IN WOMEN ≥65 YEARS WITH ONCE-MONTHLY ORAL IBANDRONATE COMPARED WITH WEEKLY BISPHOSPHONATES: SUBANALYSIS FROM THE EVALUATION OF IBANDRONATE EFFICACY (VIBE) DATABASE STUDY

被引：0

作者：

Silverman, S. ^{[1
]}

Poston, S. ^{[2
]}

Blumentals, W. ^{[3
]}

Reginster, J. -Y. ^{[4
]}

机构：

[1] Univ Calif Los Angeles, Cedars Sinai Med Ctr, Beverly Hills, CA USA

[2] GlaxoSmithKline, Res Triangle Pk, NC USA

[3] Roche, Nutley, NJ USA

[4] Univ Liege, Bone & Cartilage Metab Unit, Liege, Belgium

来源：

OSTEOPOROSIS INTERNATIONAL | 2009年 / 20卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：153 / 153

页数：1

共 34 条

[21] Comparison of the efficacy between once-monthly oral ibandronate and risedronate among Korean women with osteoporosis: a nationwide population-based study
Lee, Dong Ryul
Lee, Jungun
OSTEOPOROSIS INTERNATIONAL, 2019, 30 (03) : 659 - 666
[22] Comparison of the efficacy between once-monthly oral ibandronate and risedronate among Korean women with osteoporosis: a nationwide population-based study
Dong Ryul Lee
Jungun Lee
Osteoporosis International, 2019, 30 : 659 - 666
[23] Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study
Cooper, A.
Drake, J.
Brankin, E.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2006, 60 (08) : 896 - 905
[24] Response to once-monthly and daily oral ibandronate in women with postmenopausal osteoporosis: 2-year findings from mobile
Stepan, J. J.
Kendler, D.
Sedarati, F.
Burdeska, A.
Hughes, C.
Lorenc, R.
ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 429 - 429
[25] Efficacy and adverse event profile of once-monthly oral ibandronate: Year 1 of the mobile long-term extension study
Emkey, Ronald D.
Miller, Paul D.
Sedarati, Farhad
Silverman, Stuart L.
OSTEOPOROSIS INTERNATIONAL, 2007, 18 : S220 - S220
[26] Once-monthly and daily oral ibandronate are similarly well tolerated in women with postmenopausal osteoporosis: 2-year results from mobile
Luckey, M.
Stepan, J.
Kendler, D. L.
Feldman, D.
Lipschitz, S.
Leigh, C.
Burdeska, A.
Hiltbrunner, V
Morales-Torres, J.
OSTEOPOROSIS INTERNATIONAL, 2006, 17 : S234 - S234
[27] Large proportions of women with postmenopausal osteoporosis respond to once-monthly oral ibandronate: 2-year results from MOBILE.
Recker, RR
Luckey, M
Stakkestad, JA
Civitelli, R
Hughes, C
Mairon, N
Bonvoisin, B
Cooper, C
JOURNAL OF BONE AND MINERAL RESEARCH, 2005, 20 (09) : S395 - S395
[28] Daily and once-monthly oral ibandronate have similar safety profiles in elderly and younger women: 1-year results from the mobile study.
Miller, P
Lewiecki, M
Sol, E
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2005, 53 (04) : S194 - S194
[29] Once-monthly oral ibandronate (150mg) provides superior efficacy versus daily dosing: 2-year results from mobile
Felsenberg, D.
Greenwald, M.
Need, A.
Elizondo-Alanis, L-J
Hughes, C.
Mairon, N.
Coutant, K.
Radominski, S.
OSTEOPOROSIS INTERNATIONAL, 2006, 17 : S211 - S212
[30] Once-monthly oral ibandronate (boniva) has favorable safety and tolerability in postmenopausal women with osteoporosis: 2-year results from MOBILE.
Greenwald, M
Hawker, G
Cooper, C
Hughes, C
Mairon, N
Bonvoisin, B
Silverman, S
ARTHRITIS AND RHEUMATISM, 2005, 52 (09): : S297 - S297

← 1 2 3 4 →